0

ACTInium-J591 Radionuclide Therapy in PSMA-Detected Metastatic HOrmone-Sensitive Recurrent Prostate CaNcer

(ACTION Trial)

SC
Overseen BySharanya Chandrasekhar, M.S.
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial does not specify if you need to stop taking your current medications, but you cannot be on androgen deprivation or anti-androgen therapy to participate.

What data supports the effectiveness of the treatment Actinium-J591, Androgen Deprivation Therapy, Hormone Therapy, ADT, Stereotactic Body Radiation Therapy, Stereotactic Ablative Radiotherapy (SABR), CyberKnife?

Research shows that Actinium-225, a component similar to Actinium-J591, has shown promise in treating metastatic prostate cancer, with higher efficacy and fewer side effects compared to other treatments. This suggests potential effectiveness for Actinium-J591 in similar contexts.12345

Is the treatment Actinium-J591 safe for humans?

Research on Actinium-225, a component of Actinium-J591, shows potential for cancer treatment but highlights safety concerns due to radiotoxicity (harmful effects from radiation). In studies with mice, the treatment showed radiotoxicity at certain doses, indicating that safety depends on developing stable forms that can retain harmful byproducts.24678

How does the drug Actinium-J591 differ from other treatments for this condition?

Actinium-J591 is unique because it uses actinium-225, a radioactive substance that emits alpha particles, to target and destroy cancer cells. This approach is different from traditional treatments as it delivers radiation directly to the cancer cells, potentially reducing damage to surrounding healthy tissue.2691011

What is the purpose of this trial?

This trial is testing a new treatment that combines a special drug called Actinium-J591 with either radiation or hormone therapy. It targets patients with prostate cancer that has spread but is not clearly visible on regular scans. The drug helps make the treatments more effective by directly targeting the cancer cells.

Research Team

HN

Himanshu Nagar, M.D.

Principal Investigator

Weill Medical College of Cornell University

Eligibility Criteria

Inclusion Criteria

Pathologically (histologically or cytologically) proven diagnosis of prostate adenocarcinoma at any anatomical location (for example, prostate, metastatic site), including intraductal or ductal carcinoma, at any time before registration
Must meet study entry criteria based on the following diagnostic workup within 120 days prior to enrollment: • History and physical examination 99mTc bone scan (Must be negative or equivocal); Either CT or MRI of pelvis +/- abdomen (Must be negative or equivocal); PSMA PET scan (Must be positive with exception of local disease); Note: All 3 scans are mandatory (bone scan; CT/MR; PET)
To have adequate organ and marrow function, as defined below: a. Absolute neutrophil count (ANC) of ≥2,000/mm3 b. Hemoglobin ≥9 g/dL without need for transfusion c. Platelet count ≥150,000/mm3 and absent history or primary quantitative or qualitative platelet defect d. Serum creatinine of ≤1.5 x ULN or calculated creatinine clearance of ≥60 mL/min/1.73 m2 by Cockcroft-Gault (or determined by 24 hour urine collection) e. Serum total bilirubin ≤1.5 x ULN (unless due to Gilbert's syndrome, in which case direct bilirubin must be normal) f. Serum AST and ALT ≤1.5 x ULN
See 4 more

Exclusion Criteria

Intrapelvic lymph nodes as only site of prostate cancer recurrence
Received a platelet transfusion within 4 weeks of treatment
Biopsy-proven prostatic carcinoma with signet-ring, sarcomatoid, or neuroendocrine features (for example, small cell)
See 10 more

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive Actinium-J591 combined with radiation therapy or androgen deprivation therapy

3 months

Follow-up

Participants are monitored for safety and effectiveness after treatment

24 months

Treatment Details

Interventions

  • Actinium-J591
  • Androgen Deprivation Therapy
  • Stereotactic Body Radiation Therapy
Participant Groups
2Treatment groups
Active Control
Group I: Cohort 1Active Control2 Interventions
Group II: Cohort 2Active Control2 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Weill Medical College of Cornell University

Lead Sponsor

Trials
1,103
Recruited
1,157,000+

Convergent Therapeutics, Inc.

Collaborator

Trials
1

Findings from Research

Actinium-225 (Ac-225) PSMA radioligand therapy (RLT) shows promising efficacy in treating metastatic castration-resistant prostate cancer (mCRPC), with 81% of patients experiencing a decline in PSA levels and 60% achieving more than a 50% reduction.
The treatment is generally safe, with the most common side effect being mild to moderate xerostomia (dry mouth) reported in 73.9% of patients, indicating that Ac-225 may have fewer severe side effects compared to traditional beta-emitting therapies.
Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Prostate Cancer: A Systematic Review and Metanalysis.Parida, GK., Panda, RA., Bishnoi, K., et al.[2023]
In a study of 11 heavily pretreated patients with metastatic castration-resistant prostate cancer (mCRPC), treatment with Actinium-225 (225Ac) labeled PSMA-617 led to a significant improvement in quality of life, as measured by the NCCN-FACT-FPSI-17 questionnaire, particularly in physical and emotional symptoms.
The therapy resulted in a notable biochemical response, with 46% of patients experiencing a significant decline in Prostate Specific Antigen (PSA) levels, while the treatment was associated with manageable side effects, including some Grade 3 toxicities in a small number of patients.
Health-Related Quality-of-Life Outcomes with Actinium-225-Prostate-Specific Membrane Antigen-617 Therapy in Patients with Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer.Satapathy, S., Mittal, BR., Sood, A., et al.[2022]
The study found that actinium-225 labeled PSMA-specific tracers ([225Ac]Ac-PSMA-I&T) have a significantly higher relative biological effectiveness (RBE) of 4.2 times compared to lutetium-177 labeled tracers ([177Lu]Lu-PSMA-I&T), suggesting that actinium-225 may provide a more effective treatment for prostate cancer due to its ability to induce more complex DNA damage.
Both tracers showed similar binding characteristics to prostate cancer cells, but [225Ac]Ac-PSMA-I&T resulted in slower DNA double strand break repair kinetics, indicating that the type of radiation emitted by actinium-225 leads to more challenging DNA damage compared to lutetium-177.
In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T.Ruigrok, EAM., Tamborino, G., de Blois, E., et al.[2022]

References

Efficacy and Safety of Actinium-225 Prostate-Specific Membrane Antigen Radioligand Therapy in Metastatic Prostate Cancer: A Systematic Review and Metanalysis. [2023]
2.United Arab Emiratespubmed.ncbi.nlm.nih.gov
Production of high-purity radium-223 from legacy actinium-beryllium neutron sources. [2019]
Health-Related Quality-of-Life Outcomes with Actinium-225-Prostate-Specific Membrane Antigen-617 Therapy in Patients with Heavily Pretreated Metastatic Castration-Resistant Prostate Cancer. [2022]
4.United Arab Emiratespubmed.ncbi.nlm.nih.gov
NorthStar Perspectives for Actinium-225 Production at Commercial Scale. [2019]
In vitro dose effect relationships of actinium-225- and lutetium-177-labeled PSMA-I&T. [2022]
Preparation of an Actinium-228 Generator. [2020]
Actinium-225 conjugates of MAb CC49 and humanized delta CH2CC49. [2013]
Computer-Assisted Design of Macrocyclic Chelators for Actinium-225 Radiotherapeutics. [2021]
Radiopharmaceutical Quality Control Considerations for Accelerator-Produced Actinium Therapies. [2023]
Spectroscopic and computational investigation of actinium coordination chemistry. [2018]
Application of ion exchange and extraction chromatography to the separation of actinium from proton-irradiated thorium metal for analytical purposes. [2018]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security